Potential of transposon-mediated cellular reprogramming towards cell-based therapies

doi:10.4252/wjsc.v12.i7.527

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8313)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

497

WORD

202

HTML

4575

Figures (1-3)

369

Tables (1-1)

202

Sum=5845

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

433

Download

634

Sum=1067

Publishing Process of This Article

Item

Count

Browse

698

Download

703

Sum=1401

Jul 26, 2020 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Stem Cells. Jul 26, 2020; 12(7): 527-544
Published online Jul 26, 2020. doi: 10.4252/wjsc.v12.i7.527

Full Size Figure Download Figure

Figure 3 Timeline of transposon-mediated cellular reprogramming of porcine somatic cells to induced pluripotent stem cells (A), change in the morphology of somatic cells in the culture after transposition (B, unpublished own data), timeline of virus mediated cellular reprogramming of somatic cells to induced pluripotent stem cells (C). iPS: Induced pluripotent stem; MEF: Mouse embryonic fibroblast.

Citation: Kumar D, Anand T, Talluri TR, Kues WA. Potential of transposon-mediated cellular reprogramming towards cell-based therapies. World J Stem Cells 2020; 12(7): 527-544
URL: https://www.wjgnet.com/1948-0210/full/v12/i7/527.htm
DOI: https://dx.doi.org/10.4252/wjsc.v12.i7.527